The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients
The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are eligible for autologous stem cell transplant. The decision follows an earlier positive recommendation of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP…